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DOI 10.1016/j.ccr.2011.01.018SUMMARYCancer is a leading cause of death worldwide. Tumor cells exploit various signaling pathways to promote
their growth and metastasis. To our knowledge, the role of angiopoietin-like 4 protein (ANGPTL4) in cancer
remains undefined. Here, we found that elevated ANGPTL4 expression is widespread in tumors, and its
suppression impairs tumor growth associated with enhanced apoptosis. Tumor-derived ANGPTL4 interacts
with integrins to stimulate NADPH oxidase-dependent production of O2
. A high ratio of O2
:H2O2 oxidizes/
activates Src, triggering the PI3K/PKBa and ERK prosurvival pathways to confer anoikis resistance, thus
promoting tumor growth. ANGPTL4 deficiency results in diminished O2
 production and a reduced
O2
:H2O2 ratio, creating a cellular environment conducive to apoptosis. ANGPTL4 is an important redox
player in cancer and a potential therapeutic target.INTRODUCTION
In response to stresses such as hypoxia and inflammation in the
tumor microenvironment, tumor cells exploit various signaling
molecules to sustain and promote their growth, invasiveness,
andmetastasis (Singh et al., 2007). Aggressive tumor metastasis
and invasiveness are the main cause of mortality in patients with
cancer (Fidler, 1999). The constitutive activation of intracellular
signaling by these molecules in tumor cells leads to cellular
changes, including increased proliferation and the ability for cells
to grow beyond their original confined milieu, leading to metas-
tasis (Pani et al., 2009; Westhoff and Fulda, 2009). Among these
changes, the loss of dependence on integrin-mediated extracel-Significance
We show here that elevated expression of ANGPTL4 is widesp
resistance to tumors via autocrine adhesion mimicry. Our fin
maintain an elevated, oncogenic O2
:H2O2 ratio and, therefore
as an important player in redox-mediated cancer progression.
clonal antibodies imparts a significant decrease in in vivo tum
anoikis challenge. Our findings suggest that anticancer strateg
are viable.lular matrix contact for growth (i.e., anoikis resistance) is an
essential feature of tumor cells. However, the mechanism by
which anoikis resistance is acquired remains an unsolved
problem in cancer biology.
Although low levels of reactive oxygen species (ROS) regulate
cellular signaling and play an important role in normal cell prolifer-
ation, recent studies show that tumors exhibit an excessive
amount or persistent elevation of ROS (specifically the superoxide
anion O2
) and utilize a redox-based mechanism to evade death
by anoikis (Chiarugi, 2008; Giannoni et al., 2008; Pervaiz and
Cle´ment, 2007). Previous studies have indicated that ROS are
involved in tumor initiation, progression, and maintenance.
Furthermore, deregulated ROS production is also associatedread in tumors, and tumor-derived ANGPTL4 confers anoikis
dings that ANGPTL4 hijacks integrin-mediated signaling to
, confers anoikis resistance to tumor cells suggest ANGPTL4
Treating cancer cells with ANGPTL4-targeted RNAi or mono-
or growth and induces apoptosis in cancer cell lines upon
ies focusing on redox-based apoptosis induction in tumors
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Figure 1. Elevated Expression of ANGPTL4 in Various Tumor Types
(A) ANGPTL4 expression varied among tumors procured from different anatomic sites. Heat map profiles generated from IF images. X, Y, and Z axes represent
the length, width, and IF intensity, respectively. Representative images of normal skin and tumor samples with their corresponding heat maps are shown.
Heat maps from same anatomic sites are grouped horizontally. Results are representative of two independent experiments performed in duplicate.
Scale bars represent 200 mm.
(B) Relative ANGPTL4 mRNA and protein levels in nontumorigenic skin cell HaCaT and tumorigenic lines HSC, II-4, and A-5RT3.
(C and D) Relative ANGPTL4 mRNA and protein levels in paired human SCCs (C) or BCCs (D) and cognate PNSs. Normal human skin (NS) biopsies serve as
additional controls. Three SSCs with the highest mRNA ANGPTL4 levels corresponded to an invasive prognosis.
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 for Tumor Anoikis Resistancewith an invasive tumor phenotype. Oncogenic and mitogenic Ras
activity is superoxidedependent, and a sustained increase inROS
following the overexpression of Nox1 (the catalytic subunit of
NADPH oxidase) leads to cell transformation and aggressive
tumormetastasis (Komatsu et al., 2008;Suhet al., 1999). Elevated
production of ROS following activation of the c-Met proto-onco-
gene leads to cell transformation and malignant growth (Ferraro
etal., 2006), andRac-dependent redoxsignals increase thesecre-
tion of metalloproteinases and induce epithelial-mesenchymal
transition (Wu, 2006), two key features of invasive cancers. Thus,
a clear understanding of the underlying redox-based anoikis
escape mechanism and its connection to malignancy will provide
insight into therapeutic interventions.
The secreted protein angiopoietin-like 4 (ANGPTL4) was
recently linked to tumor progression. ANGPTL4 was previously
identified as a paracrine and, possibly, endocrine regulator of
lipid metabolism (Oike et al., 2005) and a target of peroxisome
proliferators-activated receptors (PPARs) (Kersten et al., 2000).
ANGPTL4 is expressed in numerous cell types, such as adipo-
cytes and hepatocytes, and is upregulated after fasting and
hypoxia (Belanger et al., 2002; Kersten et al., 2000). Importantly,
ANGPTL4 undergoes proteolytic processing to release its
C-terminal fibrinogen-like domain (cANGPTL4), which circulates
as a monomer but whose function remains unclear. The
N-terminal coiled-coil domain of ANGPTL4 (nANGPTL4) medi-
ates ANGPTL4 oligomerization and binds to lipoprotein lipase
to modulate lipoprotein metabolism (Ge et al., 2004). Emerging
studies also implicate tumor-derived ANGPTL4 in cancer metas-
tasis via its effect on endothelial integrity. However, whether
ANGPTL4 promotes or inhibits vascular permeability and, thus,
cancer metastasis remains controversial. Several previous
studies suggest that ANGPTL4 can prevent metastasis by inhib-
iting vascular leakiness (Galaup et al., 2006; Ito et al., 2003).
Conversely, ANGPTL4 is also implicated as a pro-angiogenic
factor (Le Jan et al., 2003). Recent reports demonstrate that
ANGPTL4 is one of the most highly predictive genes associated
with breast cancer metastasis to the lung (Minn et al., 2005; Pa-
dua et al., 2008). ANGPTL4 expression is upregulated in clear
cell renal-cell carcinoma (Le Jan et al., 2003) and oral tongue
squamous cell carcinoma (SCC) (Wang et al., 2010). In addition,
tumor-derived ANGPTL4 has been shown to promote metas-
tasis by disrupting vascular integrity (Padua et al., 2008). The
reasons for these conflicting results and the underlying mecha-
nism of ANGPTL4 activity in tumor cells have not been clarified,
hampering our understanding of its precise role in cancer metas-
tasis. More importantly, the global expression pattern of
ANGPTL4 in different types of tumors, to our knowledge, has
yet to be fully investigated, and the pathological relevance of
ANGPTL4 in cancer biology remains largely undefined. Thus,
we set up to study the role of ANGPTL4 in tumor growth and
metastasis.(E) Relative HIF1a mRNA and protein levels in paired SCCs and PNSs. For qPCR
(F) Relative ANGPTL4 mRNA and protein levels in LCM epithelial cells and stroma
SCC section before and after LCM of epithelial tissue are shown in left panel. Sc
(middle panel) and immunoblotting (right panel).
(B–F) mRNA data (mean ± SD) are from two independent qPCR experiments per
keeping gene. *p < 0.05; **p < 0.01; ***p < 0.001. Immunoblot data are from three i
and transfer control. See also Figure S1.RESULTS
ElevatedExpressionofANGPTL4 inVariousTumorTypes
To examine the expression profile of ANGPTL4 in human tumors,
we screened its expression pattern on two human tumor tissue
arrays, which cover most of the common benign, malignant,
and metastatic tumors originating from various anatomic sites.
Using immunofluorescence (IF) with an anti-cANGPTL4 anti-
body, we observed widespread, elevated ANGPTL4 expression
in all epithelial tumor samples when compared to the corre-
sponding normal tissues, regardless of the anatomic sites of
origin (Figure 1A; see Figures S1A and S1B available online).
However, the IF signal level varied among different types of
tumors. Notably, the expression of ANGPTL4 increased as
tumors progressed from a benign state to an invasive/metastatic
state (Figure S1C). Next, we determined ANGPTL4 expression
on three human skin tumorigenic lines (HSC, II-4, and A-5RT3),
ten human SCC, and 13 basal cell carcinoma (BCC) biopsies
by quantitative real-time PCR (qPCR) and immunoblot analyses.
Consistent with our prior results, we observed increased
ANGPTL4mRNA and protein levels in these epithelial tumor cells
compared with the nontumorigenic human skin line HaCaT or
cognate peri-tumor normal samples (PNSs), respectively
(Figures 1B–1D). No difference was observed between normal
skin biopsies (NSs) and PNSs (Figures 1C and 1D). Interestingly,
the three SCCs expressing the highest mRNA level of ANGPTL4
corresponded to an invasive prognosis (Figure 1C), underscoring
our finding from tumor tissue arrays. In addition, polyclonal anti-
bodies against either the N or C terminus of ANGPTL4 detected
only cANGPTL4 in these tumor lines and SSCs (Figures 1B–1D;
Figure S1D and S1E). To understand the reason for the increased
expression of ANGPTL4 in tumor cells, we examined the expres-
sion of hypoxia-inducible factor 1 a (HIF1a) and PPARs in the
SCCs. We found a concomitant upregulation of HIF1a with
ANGPTL4 in SSCs than in PNSs (correlation coefficient = 0.88)
(Figure 1E; Figures S1F). No clear correlation was observed
between the expression of ANGPTL4 and the three PPAR iso-
types (Figures S1G–S1I). These results suggested that at least
for SCCs, the elevated ANGPTL4 expression reflects the tumor’s
hypoxic microenvironment. As a protein that is secreted by
tumor cells, ANGPTL4 may perform paracrine or autocrine func-
tion in tumors. Therefore, we sought to determine the source of
ANGPTL4 in tumors. We isolated epithelial tumor and stromal
tissues, the latter consisting mainly of fibroblasts, from SCCs
and PNSs, using laser capture microdissection (LCM). qPCR
and immunoblot analyses revealed that epithelial tumor cells,
rather than tumor stroma, were the major contributor of
ANGPTL4 in SCCs (Figure 1F). Furthermore, only a low, baseline
level of ANGPTL4 expression was found in normal PNS stroma
and epithelia, suggesting that ANGPTL4 may have an autocrine
role in tumors.results, data points from the same individual are linked by colored lines.
l fibroblasts from paired SCCs and PNSs. Hematoxylin and eosin images of an
ale bars represent100 mm. Microdissected tissues were processed for qPCR
formed in triplicate. Ribosomal protein L27 (L27) serves as a reference house-
ndependent experiments performed in duplicate. b-Tubulin serves as a loading
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Figure 2. Suppression of ANGPTL4 Impairs Tumorigenicity
(A) Relative ANGPTL4 mRNA and protein levels in A-5RT3 (parental), A-5RT3CTRL (scrambled control), and A-5RT3ANGPTL4 (knockdown) cells. Data (mean ± SD)
are from three independent qPCR experiments performed in triplicate. Ribosomal protein L27 (L27) serves as a reference housekeeping gene. Immunoblot data
are from three independent experiments performed in duplicate. b-Tubulin serves as a loading and transfer control.
(B) Size of xenograft tumors induced in nude mice by 53 105 of A-5RT3ANGPTL4 or A-5RT3CTRL cells 8 weeks postinoculation (n = 5 per group). Each circle repre-
sents mean size from three measurements on each mouse at week 8 (wk 8).
(C) Representative pictures of A-5RT3CTRL- and A-5RT3ANGPTL4-induced tumors (wk 8) in (B). Black arrows indicate inoculation sites.
(D and E) Tumor volume induced in ANGPTL-KO and WT mice (D), and PBS- or recombinant cANGPTL4-treated C57BL/6J WT mice (E) by B16F10 melanoma
(B16F10CTRL, control) and ANGPTL4-knockdown (B16F10ANGPTL4). Cells (13 10
6) were s.c. inoculated into each mouse (n = 6 per group). Mice (E) were treated
i.v. with either 3 mg/kg of cANGPTL4 or vehicle PBS thrice a week. Values (mean ± SEM) are from three measurements of each mouse.
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Next, we investigated the biological relevance of elevated
ANGPTL4 expression to tumor growth via RNAi. Four sets of
siRNAs targeting different segments of the ANGPTL4 sequence
were stably introduced into the metastatic skin tumor line
A-5RT3 (Mueller et al., 2001), and the subline with the highest
knockdown efficiency (A-5RT3ANGPTL4) was selected for subse-
quent studies. A nontargeting scrambled siRNA was also
integrated into A-5RT3 (A-5RT3CTRL) as a negative control.
ANGPTL4 mRNA and protein levels were suppressed by >85%
in A-5RT3ANGPTL4 as compared with the parental A-5RT3 or
A-5RT3CTRL (Figure 2A). The induction of interferon responses
has been reported as a challenge to the specificity of some
RNAi approaches (Bridge et al., 2003). To test whether the
RNAi-mediated silencing of ANGPTL4was associatedwith inter-
feron responses, we measured the expression of several key
interferon response genes by qPCR. No induction of OAS1,
OAS2, MX1, or ISGF3g was detected in A-5RT3ANGPTL4 cells
compared with either A-5RT3 or A-5RT3CTRL (Figure S2A).
As expected, the injection of A-5RT3CTRL cells into immunode-
ficient mice induced large primary tumors (1000 mm3) in all five
mice at week 8, but A-5RT3ANGPTL4-induced tumors displayed
a 90% reduction in tumor growth (Figures 2B and 2C).
A-5RT3ANGPTL4-induced tumor growth was similarly reduced,
albeit a 40% reduction, when mice were implanted with
increasing number of tumor cells (Figure S2B). To strengthen
the above observations, we subcutaneously (s.c.) implanted
B16F10 cells into ANGPTL4-knockout (KO) and control (wild-
type [WT]) mice. WT and KO mice were maintained in a
C57BL/6J background, and the B16F10 melanoma was derived
from the same background. Notably, B16F10 tumor cells im-
planted in KO mice grew slower than those implanted in WT
mice; at day 15, the average tumor volume in KO mice was
6-fold less than in WT mice (Figure 2D). The injection of
ANGPTL4-knockdown (B16F10ANGPTL4) cells into KO mice
induced little tumor growth and showed similar growth profile
in WT mice compared to control B16F10 (B16F10CTRL)-induced
tumors in KO mice (Figure 2D). Conversely, WT mice implanted
with B16F10CTRL cells and intravenously (i.v.) injected three
times a week with recombinant N-terminal histidine-tagged
cANGPTL4 showed greater tumor growth. The average tumor
volume in cANGPTL4-treated mice was 3-fold larger than
PBS-treated mice (Figure 2E; Figures S2C and S2D).
B16F10ANGPTL4-induced tumor growth was diminished in
PBS-treatedmice as compared to cANGPTL4-treatedmice (Fig-
ure 2E). Next, we reasoned that treating mice injected with
A-5RT3CTRL cells with an antibody that interferes with the action
of ANGPTL4 would recapitulate the observation made with
A-5RT3ANGPTL4 cells. To this end the monoclonal human(F) Tumor volume in nude mice injected s.c. with 5 3 105 of A-5RT3 cells and trea
of time (n = 6 per group). Each circle represents mean ± SEM from three measu
(G) Representative pictures of control IgG- or mAb11F6C4-treated nude mice (w
(H) Immunoblot of proliferation (PCNA and cyclin D1), and apoptosis (clea
A-5RT3CTRL-induced tumor biopsies. Immunoblot data are from three independen
fer control.
(I) Hematoxylin and eosin (H&E) and IF staining of A-5RT3CTRL- and A-5RT3ANGPTL4
or TUNEL) cells were identified using the indicated antibodies or assay. Sections
(H and I) All experiments were performed using tumor biopsies harvested from m
*p < 0.05; **p < 0.01; ***p < 0.00; n.s., not significant.cANGPTL4-directed antibody mAb11F6C4 was identified and
produced for our immunotherapy experiment based on its supe-
rior kon, koff, and KD values, as determined by surface plasmon
resonance (SPR) (Figure S2E and Supplemental Experimental
Procedures). Notably, inhibition of ANGPTL4 with mAb11F6C4
attenuated tumor growth in immunodeficient mice, compared
with control IgG-treated mice (Figures 2F and 2G). Immunoblot
and IF analyses of A-5RT3ANGPTL4-induced tumor biopsies indi-
cated reduced cell proliferation and enhanced cell apoptosis
than A-5RT3CTRL-induced tumors (Figures 2H and 2I). A qPCR-
focused array of A-5RT3ANGPTL4-induced tumor biopsies further
suggested increased expression of many pro-apoptotic genes,
whereas expression of cell proliferation genes was diminished
(Figure S2F and Table S1). Together, these observations clearly
support a tumor-promoting role for cANGPTL4.
ANGPTL4-Deficient Tumor Cells Showed Increased
Susceptibility to Anoikis
Anchorage-independent growth or anoikis resistance of tumor
cells, a hallmark of tumor malignancy (Hanahan and Weinberg,
2000), was investigated by tumor colony formation in soft agar
and anoikis assays (Salmon, 1984). Underscoring our in vivo
findings, the colony-forming potential of A-5RT3ANGPTL4 cells
was undermined and formed fewer (85%) tumor colonies
on soft agar than A-5RT3CTRL (Figure 3A). Furthermore,
A-5RT3ANGPTL4 was more susceptible to anoikis, having 30%
more apoptotic cells and enhanced caspase activities than
A-5RT3CTRL cells after 2 hr of anoikis (Figures 3B and 3C). The
addition of exogenous recombinant cANGPTL4 reduced the
apoptotic index of A-5RT3ANGPTL4 cells in a dose-dependent
manner (Figure 3D). Similarly, ANGPTL4 deficiency in human
keratinocytes rendered these cells 50% more susceptible to
anoikis when compared to control keratinocytes, suggesting
that a low amount of ANGPTL4 was also necessary to confer
anoikis resistance in normal epithelial cells (Figure S3A). No
difference in the apoptotic index was observed due to the
deficiency of ANGPTL4 in adhered A-5RT3 cells or keratinocytes
(Figures S3B and S3C).
ANGPTL4 Interacts with Integrins b1 and b5
Themechanism by which ANGPTL4mediates anoikis resistance
is an unanswered question. Previous studies have revealed that
anoikis is an integrin-dependent process (Chiarugi, 2008; Zhan
et al., 2004). Thus, we hypothesize that ANGPTL4 also exerts
its role in tumor cells through integrins-mediated signaling. We
examined if cANGPTL4 can interact with integrins. Indeed,
SPR and ELISA results showed that ANGPTL4 specifically inter-
acts with integrins b1 and b5, but not with b3 (Figures 3E and 3F),
and these interactions were blocked by either mAb11F6C4 orted i.v. with 30 mg/kg/week of either mAb11F6C4 or control IgG as a function
rements of each mouse.
k 8) as described in (F). White arrows indicate inoculation sites.
ved caspase-3, Bax and cleaved PARP) markers in A-5RT3ANGPTL4- and
t experiments performed in duplicate. b-Tubulin serves as a loading and trans-
-induced tumor sections. Proliferating (Ki67) and apoptotic (cleaved caspase-3
were counterstained with DAPI (blue). Scale bars represent 40 mm.
ice described in (B) and (C) at week 8 (wk 8). See also Figure S2 and Table S1.
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Figure 3. ANGPTL4 Interacts with Integrins b1 and b5 to Confer Tumor Cells Anoikis Resistance
(A) Quantification of A-5RT3CTRL and A-5RT3ANGPTL4 tumor colonies on soft agar (left panel). Values (mean ± SD) are from four independent assays performed
in triplicate. **p < 0.01.
(B) Percentage of apoptotic A-5RT3CTRL and A-5RT3ANGPT4 cells after 2 hr of anoikis, as analyzed by FACS (5000 events). The sum of Annexin V
+/PI
(early apoptosis) and Annexin V+/PI+ (late apoptosis) cells were considered apoptotic. Values (bold) denote apoptotic cells (%). Results are representative of three
independent experiments.
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S3G). ANGPTL4 deficiency did not affect the expression of integ-
rins b1, b3, and b5 (Figure S3H). An in situ proximity ligation
assay (PLA) detected ANGPTL4-integrin complexes in both
A-5RT3CTRL cells and tumors (Figure 3I; Figure S3I), confirming
that this interaction also exists in vivo. Further investigation re-
vealed that integrin activation by ANGPTL4 binding triggered
focal adhesion kinase (FAK) in A-5RT3CTRL cells and tumors,
which were reduced by >70% in A-5RT3ANGPTL4 (Figure 3J; Fig-
ure S3J). All of these findings were corroborated by results from
immunodetection of FAK on tumor biopsies (Figure 3K). Our find-
ings suggest that ANGPTL4 secreted by epithelial tumor cells
acts in an autocrine manner to hijack the integrin/FAK-regulated
pathway, conferring anoikis resistance to tumors and, thus,
sustaining tumor growth.
ANGPTL4 Elevates the O2
– Level and Maintains
a High O2
–:H2O2 Ratio in Tumor Cells
ROS can be regulated through integrin engagement, and an
elevated O2
 level allows tumor cells to avoid anoikis (Pani
et al., 2009; Pervaiz and Cle´ment, 2007). In this regard we as-
sessed whether ANGPTL4-integrin interaction regulates ROS
production in tumor cells. Using electron paramagnetic reso-
nance spectroscopy (EPR) in combination with 5-(diethoxyphos-
phoryl)-5-methyl-1-pyrroline-N-oxide (DEPMPO) spin trapping,
we measured a decrease in the O2
 level in A-5RT3ANGPTL4
compared to A-5RT3CTRL cells (Figures 4A and 4B), suggesting
that ANGPTL4 is vital in sustaining O2
 production in tumor cells.
To determine the source of O2
, similar experiments were per-
formed using specific inhibitors that block the mitochondrial
respiratory chain complex I and membrane-bound NADPH
oxidase, which are two major producers of O2
 in mammalian
cells (Giannoni et al., 2008). Treatment of tumor cells with rote-
none, a mitochondrial respiratory chain complex I inhibitor (Irani
et al., 1997), did not alter cellular O2
 level (Figures 4A and 4B),
suggesting that this complex has little role in generating O2
 in
tumors. Further excluding mitochondria as the source of
ANGPTL4-mediated O2
 generation, qPCR analysis showed
no change in the expression of selected genes in the methio-
nine/homocysteine metabolic cycle (Figure S4A), as previously
studied in diabetic rodent hepatocytes (Wang et al., 2007). In
contrast the O2
 level was abrogated by using two different
NADPH oxidase inhibitors (Ushio-Fukai and Nakamura, 2008),(C) Relative activities of caspases 2, 3, 6, 8, 9 in A-5RT3ANGPTL4 cells compared to
SD) are from three independent experiments performed in triplicate. *p < 0.05; **
(D) Percentage of anoikis-induced apoptotic A-5RT3ANGPT4 cells in the presen
(5000 events). Vehicle (PBS)-treated A-5RT3CTRL and A-5RT3ANGPT4 cells served
(E and F) Representative sensorgrams of three independent experiments showing
b5 (F). Integrin b3 (75 nM) did not show any detectable interaction (F, dotted red
bilized protein. KD 107 M was determined after global fitting (Langmuir 1:1 mo
(G and H) Representative sensorgrams showing dose-dependent blocking of inte
indicated concentrations of mAb11F6C4.
(I and J) In situ PLA detection of ANGPTL4:integrin b1 (I, left two panels), ANGPTL4
and A-5RT3CTRL-induced tumor biopsies. Higher magnification images are shown
nuclei are stained blue by Hoechst dye. Negative controls were performed with o
(K) Immunoprecipitation and immunodetection of ANGPTL4, integrin b1, integrin
Rac1 (GTP-Rac1) from the indicated tumor sections. A configuration-specific
GTP-Rac1. Total FAK serves as a loading and transfer control.
Experiments in (I)–(K) were performed using tumor biopsies described in Figures 2
results. See also Figure S3.diphenylene iodonium (DPI) and apocynin (Figures 4A and 4B).
ROS generated through the involvement of the small GTPase
Rac1 and NADPH oxidase upon integrin engagement exert
a mandatory role in transmitting a prosurvival signal that ensures
that tumor cells escape from anoikis (Giannoni et al., 2008; Jone-
son and Bar-Sagi, 1998). Comparative immunoblot analyses
of anti-cANGPTL4 immunoprecipitates from A-5RT3CTRL- and
A-5RT3ANGPTL4-induced tumor lysates detected integrins b1
and b5, along with phosphorylated FAK and active GTP-bound
Rac1, in A-5RT3CTRL-induced tumors, all of which were reduced
in A-5RT3ANGPTL4-induced tumors (Figure 3K). To further validate
the relevance of Rac1 in ANGPTL4-mediated O2
 production,
we transiently transfected A-5RT3CTRL and A-5RT3ANGPTL4 cells
with dominant-negative Rac1 (T17N) and constitutively active
Rac1 (G12V), respectively. We measured a diminished O2
 level
in the former and, conversely, an obviously rescued O2
 produc-
tion in the latter. The percentage of inhibition and recovery
was consistent with the 65% transfection efficiencies, as
estimated using a GFP-expressing vector. The requirement of
Rac1 suggested a Rac1-engaged Nox (i.e., Nox1-3)-dependent
mechanism for O2
 production. Because Nox 3 is expressed
predominantly in the inner ear (Paffenholz et al., 2004), we exam-
ined the expression of Nox1 and Nox2 in A-5RT3 (Figure S4B).
Next, we performed Nox1 and Nox2 knockdown (Nox1 kd and
Nox2 kd, respectively) in A-5RT3CTRL and A-5RT3ANGPTL4 cells
(Figure S4C), and measured the O2
 level using EPR (Figures
4A and 4B). Results indicated that Nox1 NADPH oxidase is the
predominant source of ANGPTL4-mediated O2
 generation in
tumor cells. The O2
 level was completely abolished by super-
oxide scavenger Tiron, which serves as a negative control
for superoxide measurements (Figures 4A and 4B). These data
were reproduced by a chemiluminescence assay using
2-methyl-6-(4-methoxyphenyl)-3, 7-dihydroimidazo[1,2-a]pyra-
zin-3-one hydrochloride (MCLA) (Figure 4C) (Mu¨nzel et al.,
2002). Next, we measured the level of H2O2 in tumor cells in
the presence of a specific catalase inhibitor, 3-amino-l, 2, 4-tria-
zole (Chance et al., 1979; Wagner et al., 2005). H2O2 levels were
higher in A-5RT3ANGPTL4 than A-5RT3CTRL cells (Figure 4D). Nox1
kd did not affect the H2O2 level, suggesting that ANGPTL4
modulated H2O2 production, linked to an unknown mechanism
(Figure S4D). Notably, the lower O2
 level and O2
:H2O2 ratio
were concurrent with 3-fold more apoptosis and enhanced cas-
pase activities within 2 hr of anoikis in A-5RT3ANGPTL4 comparedA-5RT3CTRL cells (assigned value of one) after 2 hr of anoikis. Values (mean ±
p < 0.01.
ce of increasing exogenous recombinant cANGPTL4, as analyzed by FACS
as controls for comparison. The apoptotic index is described in (B).
binding profiles between immobilized-ANGPTL4 and integrin b1 (E) or integrin
line). Sensorgrams were corrected against a reference flow cell with no immo-
del) using Scrubber2.
grin b1 (G) and integrin b5 (H) to immobilized-ANGPTL4 by preinjection with the
:integrin b5 (I, right two panels), and phosphorylated FAK (J) in A-5RT3ANGPTL4-
(I, second and fourth panels; J, right panel). PLA signals are shown in red, and
nly anti-nANGPTL4 (I) or anti-FAK (J) antibodies. Scale bars represent 40 mm.
b5, total FAK, phosphorylated FAK (pY397FAK), total Rac1, and GTP-bound
monoclonal anti-Rac-GTP antibody was used for immunoprecipitation of
B and 2C. All experiments in (B)–(K) were repeated three times with consistent
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Figure 4. ANGPTL4 Elevates O2
– Level and Maintains a Relatively High O2
–:H2O2 Ratio in Tumor Cells
(A and E) Representative EPR spectra of DEPMPO-superoxide spin adduct from A-5RT3CTRL and A-5RT3ANGPTL4 cells (A) or A-5RT3CTRL- and A-5RT3ANGPTL4-
induced tumors (E) in the absence or presence of indicated chemicals or inhibitors. A-5RT3CTRL and A-5RT3ANGPTL4 cells were transiently transfected either with
vector expressing Rac1(T17N) or Rac1(G12V), or with ON-TARGETplus siRNA against either Nox1 (Nox1 kd) or Nox2 (Nox2 kd). The superoxide adduct of
DEPMPO has hyperfine splitting constants of: aN = 13.13 gauss; aP = 55.61 gauss; a
b
H = 13.11 gauss; and a
g
H = 0.71, 0.42, 0.7, 0.25, and 0.6 gauss.
(B and F) EPR signal intensity at 3480 gauss fromA-5RT3CTRL and A-5RT3ANGPTL4 cells in (A) or tumors in (E).Tiron-treatedmeasurements serve as negative signal
controls.
(C) Measurement of O2
 levels using theMCLA assay in A-5RT3CTRL and A-5RT3ANGPTL4 cells in the absence or presence of the indicated chemicals or inhibitors.
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Cancer Cell
ANGPTL4 Sustains O2
 for Tumor Anoikis Resistanceto A-5RT3CTRL cells (Figures 3B, 3C, and 4A–4D). Accordingly,
we observed a reduced O2
 level in A-5RT3ANGPTL4-induced
tumors compared to A-5RT3CTRL-induced tumors (Figures 4E
and 4F), which was associated with increased apoptosis (Fig-
ure 2H and 2I; Figure S2F).
To underscore the relevance of these findings to other
cancers, similar experiments were performed using the breast
cancer line MDA-MB-231, after using mAb11F6C4 to dose
dependently neutralize endogenous cANGPTL4. We showed
earlier that mAb11F6C4 was able to block cANGPTL4-integrin
interaction (Figures 3G and 3H; Figures S3D–S3G). Consistent
with the above results, the inhibition of cANGPTL4 in MDA-
MB-231 reduced the O2
 level (Figures S4E–S4G), lowered the
O2
:H2O2 ratio (Figure S4H), and enhanced apoptosis and cas-
pase activities (Figures S4I and S4J). Nox1 kd (Figure S4K) but
not Nox2 kd reduced ANGPTL4-mediated O2
 production
(Figures S4E–S4G) with little effect on H2O2 production (Fig-
ure S4L). Together, these findings indicate that ANGPTL4
protects tumor cells from anoikis via an NADPH oxidase-depen-
dent O2
 generation mechanism.
ANGPTL4-Mediated O2
– Activates the Src, PI3K/PKBa,
and ERK Survival Pathways
Previous reports have shown that ROS produced via integrin
engagement oxidizes and activates Src, which stimulates the
ERK and PKBa prosurvival pathways (Giannoni et al., 2008,
2009; Pani et al., 2009). Both pathways regulate the subcellular
localization or stability of BH3-only apoptotic proteins (e.g.,
Bad and Bim), which are essential for executing anoikis (Bouillet
and Strasser, 2002). Thus, we asked whether ANGPTL4-integrin
engaged O2
 generation employs these downstream signaling
pathways tomodulate tumor cell behavior. Immunoblot analyses
revealed diminished expression of oxidized/activated Src, phos-
phorylated PKBa, and ERK1 in A-5RT3ANGPTL4-induced tumors
and A-5RT3ANGPTL4 cells (Figure 5A, and left panel of Figure 5B).
Similar immunoblot analyses performed in the presence of DPI
and with Nox1 kd cells revealed reduced Src, PKBa, and ERK1
activation, emphasizing the role of O2
 in their activities (Fig-
ure 5B). The inhibition of PI3K by LY294002 and Wortmannin,
a pivotal upstream mediator of PKBa, caused 4-fold more
apoptosis of tumor cells upon anoikis challenge, reaching levels
comparable to those of A-5RT3ANGPTL4 cells (Figure 5C). In addi-
tion, inhibition of MEK1/2, the upstream signal of ERK1, by
PD98059 also resulted in an enhancement of apoptotic cell
numbers, albeit to a lesser extent (50%) compared to PI3K
inhibitors (Figure 5C). These results suggest that the PI3K/
PKBa and ERK1/2 downstream survival pathways are modu-
lated and exploited by ANGPTL4 engagement in tumor cells,
the former being the predominant pathway.
The 14-3-3 adaptor protein is known to act downstream of
the aforementioned survival pathways by sequestering pro-
apoptotic Bad from the mitochondria to prevent apoptosis
(She et al., 2005). In agreement with these previous findings,
the number of 14-3-3/Bad complexes and 14-3-3b/s proteins(D) Measurement of H2O2 levels using the Amplex red assay in A-5RT3CTRL and
(B–D and F) Values were normalized to total proteins and presented as mean ±
*p < 0.05; **p < 0.01; ***p < 0.001; n.s., not significant.
Vehicle-treated A-5RT3CTRL cells (B and C) and A-5RT3CTRL-induced tumor (F) swas reduced by 70% in A-5RT3ANGPTL4-induced tumors
(Figures 5D–5F). TheNa+/H+ exchanger 1 (NHE), which positively
influences cell proliferation by maintaining an alkaline intracel-
lular environment (Akram et al., 2006), was also diminished in
A-5RT3ANGPTL4-induced tumors (Figure 5D), indicating that
NHE plays a subsidiary role in ANGPTL4-mediated tumor cell
growth. Upon oxidant challenge in tumor cells, the induction of
superoxide dismutase (SOD) expression is muted, allowing
tumor cell proliferation (Oberley, 2001; Pervaiz and Cle´ment,
2007). Indeed, we found that cytosolic Zn/CuSOD expression
was enhanced in A-5RT3ANGPTL4-induced tumors (Figure 5D),
which contribute to a reduced O2
:H2O2 ratio via an indirect
but linked mechanism (Figure 4D).
ANGPTL4 Deficiency Abrogates O2
– Production
and Sensitizes Cancer Cells to Anoikis
Our results revealed that the suppression of ANGPTL4, either by
RNAi (Figures 4A–4C) or inhibition with mAb11F6C4 (Figures
S4E–S4G), results in a dose-dependent reduction of O2
 levels.
To underscore the importance of ANGPTL4 in the regulation of
O2
 production, maintenance of a high O2
:H2O2 ratio, and,
hence, tumor survival, we examined the impact of reduced
ANGPTL4 on anoikis in nine different cancer cell lines, in addition
to A-5RT3 and MDA-MB-231 cells. Treatment with mAb11F6C4
resulted in a dose-dependent reduction of O2
 levels (40%–80%
for 6 mg/ml mAb11F6C4) (Figure 6A; Figure S5A), a reduction in
the O2
:H2O2 ratio (70%–90% for 6 mg/ml mAb11F6C4) (Fig-
ure 6B; Figure S5B), a 3- to 8-fold increase in the caspase activ-
ities (Figure 7A; Figure S6A), and 30%–60% more apoptotic
tumor cells (Figure 7B; Figure S6B), all indicatingweakened anoi-
kis resistance. A higher percentage of apoptotic tumor cells was
also observed using inducible RNAi against ANGPTL4 in the
MDA-MB-231 line (Figure S6C). These findings indicate that
ANGPTL4-mediated O2
 production for anoikis resistance may
be a common feature in tumor cells. Taken together, our study
showed that tumor-secreted ANGPTL4 interacted with integrins
in an autocrine fashion to stimulate NADPH oxidase-dependent
generation of O2
, promoting a high O2
:H2O2 ratio, and conse-
quently activating downstream PI3K/PKBa and ERK activities
(Figure 8).
DISCUSSION
The loss of dependence on integrin-mediated ECM contact for
growth (i.e., anoikis resistance) is an essential feature of tumor
cells, but the mechanism by which anoikis resistance is acquired
is a central problem in cancer biology. Our findings demon-
strated that ANGPTL4-mediated integrin engagement activates
ROS production, which leads to a prosurvival signal and sus-
tained anchorage-related signals even in the absence of ECM
and cell-cell contact. We showed that cANGPTL4 was detected
and elevated in many human tumor cells and was predominantly
secreted by proliferative tumor epithelial cells. cANGPTL4
specifically binds to integrins b1 and b5 on tumor cells andA-5RT3ANGPTL4 cells. Arbitrary relative O2
:H2O2 ratios are shown in boxes.
SEM. Data are from three independent experiments performed in triplicate.
erve as cognate controls. See also Figure S4.
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Figure 5. ANGPTL4-Mediated O2
– Regulates Src and Promotes the PI3K/PKBa and ERK Survival Pathways
(A and D) Immunoblot of the indicated proteins in A-5RT3ANGPTL4- and A-5RT3CTRL-induced tumor biopsies. Values aremean from four independent experiments.
c-Src (A) and b-tubulin (D) serve as loading and transfer controls, respectively.
(B) Immunoblot of the indicated proteins in A-5RT3ANGPTL4 and A-5RT3CTRL cells in the absence or presence of 20 mM DPI, and in Nox1 kd A-5RT3ANGPTL4 and
A-5RT3CTRL cells. Cells were suspended for 0, 1, and 2 hr (S0h, S1h, and S2h, respectively). Cell lysates were labeled with 100 mM N-(biotinoyl)-N
0-(iodoacetyl)
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Figure 6. ANGPTL4 Maintains a Relatively High O2
–:H2O2 Ratio in Tumor Cells
Measurement of O2
 (A) andH2O2 (B) levels in three different tumor lines byMCLA assay and Amplex red assay, respectively. H2O2wasmeasured in the presence
of the specific catalase inhibitor, 3-amino-l, 2, 4-triazole. Arbitrary relative O2
:H2O2 ratios (B) are shown in boxes. Values (mean ± SD) are normalized to the total
protein content. Three independent experiments were performed with consistent results. *p < 0.05; **p < 0.01. See also Figure S5.
Cancer Cell
ANGPTL4 Sustains O2
 for Tumor Anoikis Resistanceactivates FAK and Rac1, which further stimulates NADPH
oxidase-mediated O2
 production via an autocrine pathway.
However, it is conceivable that in tissues/organs, expressing
high levels of cANGPTL4 in proximity to the tumor sitemay trans-
mit a paracrine signal. Although integrins alone are not onco-
genic, integrin-mediated signaling is often required to enable
tumor survival and influence tumor growth (Desgrosellier and
Cheresh, 2010). The pro-oxidant intracellular environment led
to redox-mediated activation of the Src machinery and, there-
fore, stimulated downstream PI3K/PKBa and ERK prosurvival
pathways. This further triggered the 14-3-3 adaptor protein to
sequester the pro-apoptotic Bad protein from mitochondria,
conferring resistance to anoikis and favoring tumor survival
and growth.
The dysregulation of intracellular ROS levels, resulting in an
excessive level or persistent elevation of ROS, has been linked
to tumor growth, invasiveness, andmetastasis. Indeed, elevated
levels of ROS are detected in almost all cancers (Liou and Storz,
2010). An elevated O2
 or O2
:H2O2 ratio is particularly impor-
tant for cancer cells to sustain their tumorigenicity and meta-
static potential (Cle´ment and Pervaiz, 2001; Pervaiz andethylenediamine to evaluate the Src redox state. An HRP-Streptavidin immuno
immunoprecipitate was probed with anti-c-Src for normalization. Values (mean
are representatives of three independent experiments.
(C) Percentage of apoptotic A-5RT3ANGPTL4 and A-5RT3CTRL cells, treated with eit
2 hr of anoikis challenge and analyzed by FACS (5000 events). Apoptotic index as
considered apoptotic. Values are mean from three independent experiments.
(E) In situ PLA detection of 14-3-3:Bad complexes in indicated tumor sections an
were counterstained with Alexa 488-phalloidin for actin stress fibers (green). Nega
representative of three independent experiments. Scale bars represent 40 mm.
(F) Number (mean ± SD) of 14-3-3:Bad complexes (E, right panel) was calculatedCle´ment, 2007). We found that the disruption of ANGPTL4-
mediated redox signaling via genetic and antibody-mediated
suppression of ANGPTL4 essentially reduced the activities of
FAK, Rac1, and O2
 production. These changes resulted in an
increase in tumor cells’ sensitivity to anoikis and impaired tumor-
igenesis. ANGPTL4-stimulated NADPH oxidase activity, leading
to O2
 production, can be inhibited NADPH oxidase inhibitors,
but not by the mitochondrial complex I inhibitor rotenone. This
suggests that O2
was ‘‘purposely’’ and enzymatically produced
by NADPH oxidase, rather than as a by-product of mitochondrial
activity. Two survival pathways, the PKBa and ERK, which have
been shown to exert anoikis-suppressing effects (Westhoff and
Fulda, 2009; Zhan et al., 2004), were complementarily employed
by ANGPTL4 to confer resistance to anoikis in tumor cells.
The tumor-promoting role of inflammation in the tumor micro-
environment is well recognized (Aggarwal and Gehlot, 2009).
PPARg and d/b play major roles in the regulation of inflammation
and are implicated in tumorigenesis (Peters and Gonzalez, 2009;
Murphy and Holder, 2000). Although no correlation between the
expression of either PPARg or d/b, and their target gene
ANGPTL4, was observed in our analysis of PNSs and SCCs,blot performed on the anti-Src immunoprecipitate showing reduced Src. The
± SD) represent the mean fold change against the value at S0h. Data shown
her MEK inhibitor PD98059 or PI3K inhibitors LY294002 andWortmannin, after
described in Figure 3B. Sum of Annexin V+/PI and Annexin V+/PI+ cells were
d cells. PLA signals are red dots, and Hoechst-stained nuclei are in blue. Cells
tive controls were performed with only anti-14-3-3 antibodies. Data shown are
from 200 cells (n = 3; 600 cells total) using BlobFinder software. ***p < 0.001.
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Figure 7. Deficiency of ANGPTL4 Activates Caspase Activities and Induces Apoptosis upon Anoikis in Tumor Cells
(A) Relative activities of caspases 2, 3, 6, 8, and 9 were measured after 2 hr of anoikis. Fold increase of caspase activities in mAb11F6C4 (6 mg/ml)-treated cells
was calculated by comparing with the caspase activities of cells treated with preimmune IgG (6 mg/ml). Values (mean ± SD) are from three independent exper-
iments with consistent results.*p < 0.05; **p < 0.01.
(B) Percentage of apoptotic cells in three tumor lines after 2 hr of anoikis as analyzed by FACS (5000 events). Tumor cells were treated with 10 mg/ml of control IgG
or mAb11F6C4. Apoptotic index is as described in Figure 3B. Results are mean from three independent experiments. p < 0.05. See also Figure S6.
Cancer Cell
ANGPTL4 Sustains O2
 for Tumor Anoikis Resistancewe cannot exclude their involvement and/or other oncogenic
pathways or cell types in the tumor microenvironment, which
enhanced the expression of cANGPTL4 in tumors. It is also
conceivable that PPARs in cancer-associated fibroblasts play
a more dominant role in the regulation of epithelial tumor growth.
Indeed, PPARb/d-deficient fibroblasts can increase the prolifer-
ation of normal epithelial cells and SCCs via regulation of the
interleukin-1 signaling pathway (Chong et al., 2009). A dysregu-
lated inflammatory response promotes tumorigenesis and
malignancy by stimulating ROS production (Aggarwal and
Gehlot, 2009). Although not examined in this study, we cannot
rule out the possibility that other mechanisms to produce O2
,
such as cytosolic 5-lipooxygenase, may act in conjunction with
ANGPTL4-stimulated NADPH oxidase activity to maintain an
elevated intracellular O2
 level for tumor growth (Chiarugi and
Fiaschi, 2007). Despite inconclusive findings from clinical trials
on the effect of antioxidants on cancer (Blot et al., 1993; Omenn
et al., 1994; Hennekens et al., 1996; Lee et al., 1999), our findings
that the specific inhibition of ANGPTL4-mediated integrin
signaling and intracellular O2
 production induce tumor cell
apoptosis suggest that anticancer therapeutics focusing on
redox-based apoptosis induction remain an exciting and viable
strategy.
EXPERIMENTAL PROCEDURES
Human Tumor Samples
Human BCC biopsies and SCC biopsies along with their paired PNSs were
provided by J.Y.P., S.H.T., and purchased from USA Asterand, plc., Detroit,
MI. BCC samples, SCC samples, and PNSs, inclusive of epithelia and stroma,
were subjected to protein and RNA extraction for immunoblotting and qPCR
analyses, respectively. The study was approved by National Healthcare Group
Domain-Specific Review Boards (NHG-DSRB). All the tumor samples had
been de-identified prior to the analyses.412 Cancer Cell 19, 401–415, March 15, 2011 ª2011 Elsevier Inc.Tumorigenicity Assay
BALB/c athymic nude femalemice (20–22 g), aged 5–6weeks, andWTC57BL/
6J female mice (20–25 g), aged 6–8 weeks, were purchased from A*STAR
Biological Resources Centre (Singapore). C57BL/6J female WT and
ANGPTL4-KO mice were used (Koster et al., 2005). The animal studies were
approved and carried out in compliance with the regulation from Institutional
Animal Care and Use Committee (IACUC0092), NTU. For nude mice experi-
ments, 5 3 105 cells (A-5RT3CTRL or A-5RT3ANGPTL4) were injected s.c. into
the interscapular region of each nude mouse (n = 5). The injection site was
rotated to avoid site bias. The injected tumor cells were allowed to grow for
8 weeks. The xenograft tumors were externally measured with a Vernier
caliper every other day, and tumor volume was estimated using the equation:
V = (L 3 W2)/2, where L and W are the length of the major and minor axis of
the tumor, respectively. To test the effect of the number of injected cells on
tumorigenicity, nude mice were inoculated with 0.5 3, 2 3, and 8 3 106
A-5RT3CTRL or A-5RT3ANGPTL4 cells as above. Experiments were terminated
at week 4 according to IACUC protocol because tumor volume in the
8 3 106 inoculation group approached 3000 mm3.
For the antibody treatment, nudemice (n = 6) were implanted with A-5RT3 as
above. One week postimplantation, 30 mg/kg/week of either mAb11F6C4 or
isotype control IgG was i.v. administered for 4 weeks. The dose of antibody
and delivery mode were consistent with studies using mAb14D12, another
anti-ANGPTL4 mAb27 (Desai et al., 2007). KO mice and cANGPTL-treated
C57BL/6J mice studies were performed as previously described (Sun and
Lodish, 2010). Briefly, 1 3 106 B16F10CTRL (scrambled control) or
B16F10ANGPTL4 (ANGPTL4 knockdown) cells were s.c. injected into the inter-
scapular region of the indicated mice (n = 4–6). Mice were i.v. treated with
either 3 mg/kg of cANGPTL4 or control PBS three times a week. Animals
were monitored and tumor volumes measured as above. Mice were sacrificed
at the end of the experiment, and tumors were harvested for further analyses.In Situ PLA
Duolink in situ PLA (Olink Bioscience) was performed on tumor biopsies or
cells as described (Tan et al., 2009). The paired-primary antibodies used in
the present study were rabbit anti-p(Y397)FAK and mouse anti-FAK anti-
bodies, rabbit anti-pan-14-3-3 and mouse anti-BAD antibodies, and mouse
anti-cANGPTL4 with either rabbit anti-b1, b3, or b5 integrin antibodies. As a
Figure 8. ANGPTL4-Mediated Regulation of O2
– Production in
Tumors
In an autocrinemanner, tumor-derived ANGPTL4 specifically binds to integrins
b1 or b5 and subsequently activates FAK and Rac1 activities, which further
activates the NADPH oxidase-dependent generation of ‘‘onco-ROS’’ O2
,
promoting a relatively high O2
:H2O2 ratio in tumor cells. This pro-oxidant
intracellular milieu, which may subsidiarily be maintained through NHE, favors
cell survival and proliferation by oxidizing/activating the Src machinery and,
therefore, stimulates its downstream PI3K/PKBa- and ERK-mediated survival
pathways. This further triggers the 14-3-3 adaptor protein to sequester pro-
apoptotic Bad from mitochondria to prevent apoptosis and favor cell survival.
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 for Tumor Anoikis Resistancenegative control, PLA was performed using only anti-FAK, anti-pan-14-3-3, or
anti-nANGPTL4 antibodies, respectively. Briefly, sections/cells were fixedwith
4% paraformaldehyde for 15 min. The slides were washed twice with PBS,
blocked for 1 hr at room temperature with 2% BSA in PBS containing 0.1%
Triton X-100, followed by incubation with the indicated antibody pairs over-
night at 4C. PLA was performed as recommended by the manufacturer.
Images were taken using an LSM710 confocal laser scanning microscope
with a Plan-Apochromat 633/1.40 Oil objective and ZEN 2008 software
(Carl Zeiss).
Measurement of O2
– and H2O2
Production of O2
 from tumor cells wasmeasured using anO2
-sensitive lucif-
erin derivative, MCLA (Invitrogen). Cells (5 3 104) were trypsinized, washed,
lysed in Krebs buffer, and treated either individually or combinatorially for
0.5 hr with the following chemicals: 10 mM Tiron, 20 mM diphenyleneiodonium
chloride (DPI) or 500 mM apocynin, 50 mM rotenone, and 3 or 6 mg/ml mono-
clonal humananti-cANGPTL4 antibodymAb11F6C4.MCLA (2 mM)was added,
and the luminescent signal was recorded immediately thereafter for 1 min with
a GloMax 20/20 Luminometer (Promega). Intracellular H2O2 was measured as
previously described (Wagner et al., 2005). We performed two control experi-
ments to verify that we were measuring H2O2. The specificity of the assay for
H2O2 was verified with catalase, and the degradation of H2O2 or inhibition of
the assay system by the sample was analyzed by determining the recovery
of exogenously added H2O2. The fold change in the O2
:H2O2 ratio of
A-5RT3ANGPTL4 andmAb11F6C4-treated tumor cells was determined by direct
comparison with the value of either A-5RT3CTRL or control IgG-treated tumor
cells, which were arbitrarily assigned the value of one.Statistical Analyses
Statistical significance between two groups was analyzed using unpaired
nonparametric test (Mann-Whitney test) or with a Student’s t test (SPSS,
Inc.). All statistical tests were two sided. A p value of %0.05 was considered
significant.
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